Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Medical Research Journal
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Focus and Scope

open access

Vol 5, No 2 (2020)
Original article
Published online: 2020-06-15
View PDF Download PDF file
Get Citation

A comparison of four commercial kits used for isolating circulating cell-free DNA: QuickGeneMINI8L (Kurabo), Maxwell RSC cfDNA Plasma Kit (Promega), cfKapture 21 Kit (MagBio), and QIAamp MinElute ccfDNA Kit (Qiagen)

Katarzyna Boguszewska-Byczkiewicz1, Dariusz Jarych2, Izabela Drożdż3, Hamed Hamed Al Huwaidi4, Izabela Zawlik56, Agnieszka Kołacińska17
DOI: 10.5603/MRJ.a2020.0021
·
Medical Research Journal 2020;5(2):92-99.
Affiliations
  1. Department of Surgical Oncology, Copernicus Provincial Multidisciplinary Centre of Oncology and Traumatology, Paderewskiego 4, 93-510 Łódź, Poland
  2. Laboratory of Personalized Medicine and Laboratory of Biotechnology, Bionanopark Ltd Poland, Duboisa 114/116, 93-465 Lodz, Poland
  3. Department of Clinical Genetics, Medical University of Lodz, Poland
  4. Medical University of Łódź, Tadeusza Kościuszki 4, 90-419 Łódź, Poland
  5. Department of Genetics, Institute of Medical Sciences, Medical College, University of Rzeszow, aleja Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland
  6. Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, Medical College, University of Rzeszow, aleja Tadeusza Rejtana 16C, 35-310 Rzeszów Rzeszów, Poland
  7. Department of Head and Neck Cancer Surgery, Paderewskiego, 93-510 Łódź, Poland

open access

Vol 5, No 2 (2020)
ORIGINAL ARTICLES
Published online: 2020-06-15

Abstract

A minimally-invasive alternative to surgical biopsies is a liquid biopsy (LB), a technique that has recently revolutionized the management of a number of tumors. One potential target biomarker of LB is cell-free DNA (cfDNA), which can act as a very sensitive indicator for certain tumors. Currently, clinical efforts are focused on increasing the quality of the cfDNA isolated for analysis. The present study compares the efficiency of isolation by four commercial kits: QuickGeneMINI8L (Kurabo), Maxwell RSC cfDNA Plasma Kit (Promega), cfKapture 21 Kit (MagBio), and QIAamp MinElute ccfDNA Kit (Qiagen). In each case, cfDNA was isolated from three plasma samples and one serum sample. Available method for the isolation give the ability to enrich optimal diagnostic quantity of cfDNA. cfDNA can be successfully separated using all investigated kits. The greatest efficiency was demonstrated by the QIAamp MinElute ccfDNA Kit (Qiagen) and cfKapture 21 (MagBio). Large amounts of cell-free DNA can be successfully isolated from small volumes of plasma.

Abstract

A minimally-invasive alternative to surgical biopsies is a liquid biopsy (LB), a technique that has recently revolutionized the management of a number of tumors. One potential target biomarker of LB is cell-free DNA (cfDNA), which can act as a very sensitive indicator for certain tumors. Currently, clinical efforts are focused on increasing the quality of the cfDNA isolated for analysis. The present study compares the efficiency of isolation by four commercial kits: QuickGeneMINI8L (Kurabo), Maxwell RSC cfDNA Plasma Kit (Promega), cfKapture 21 Kit (MagBio), and QIAamp MinElute ccfDNA Kit (Qiagen). In each case, cfDNA was isolated from three plasma samples and one serum sample. Available method for the isolation give the ability to enrich optimal diagnostic quantity of cfDNA. cfDNA can be successfully separated using all investigated kits. The greatest efficiency was demonstrated by the QIAamp MinElute ccfDNA Kit (Qiagen) and cfKapture 21 (MagBio). Large amounts of cell-free DNA can be successfully isolated from small volumes of plasma.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

liquid biopsy, breast cancer, cell-free DNA

About this article
Title

A comparison of four commercial kits used for isolating circulating cell-free DNA: QuickGeneMINI8L (Kurabo), Maxwell RSC cfDNA Plasma Kit (Promega), cfKapture 21 Kit (MagBio), and QIAamp MinElute ccfDNA Kit (Qiagen)

Journal

Medical Research Journal

Issue

Vol 5, No 2 (2020)

Article type

Original article

Pages

92-99

Published online

2020-06-15

Page views

1295

Article views/downloads

1009

DOI

10.5603/MRJ.a2020.0021

Bibliographic record

Medical Research Journal 2020;5(2):92-99.

Keywords

liquid biopsy
breast cancer
cell-free DNA

Authors

Katarzyna Boguszewska-Byczkiewicz
Dariusz Jarych
Izabela Drożdż
Hamed Hamed Al Huwaidi
Izabela Zawlik
Agnieszka Kołacińska

References (31)
  1. Ponti G, Manfredini M, Tomasi A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Crit Rev Oncol Hematol. 2019; 141: 36–42.
    CrossRefPubMed
  2. Mandel P, Métais P. Les acides nucléiques du plasma sanguin chez l’homme. C R Séances Soc Biol. 1948; 142: 241–243.
  3. Keup C, Benyaa K, Hauch S, et al. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. Cell Mol Life Sci. 2020; 77(3): 497–509.
    CrossRefPubMed
  4. Shaw JA, Guttery DS, Hills A, et al. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clin Cancer Res. 2017; 23(1): 88–96.
    CrossRefPubMed
  5. Quandt D, Dieter Zucht H, Amann A, et al. Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget. 2017; 8(29): 48507–48520.
    CrossRefPubMed
  6. Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010; 7(6): 340–347.
    CrossRef
  7. Shirkavand A, Boroujeni ZN, Aleyasin SA. Examination of methylation changes of , , , and genes in peripheral blood DNA in breast cancer patients. Indian J Cancer. 2018; 55(4): 366–371.
    CrossRefPubMed
  8. Ma F, Guan Y, Yi Z, et al. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2020; 146(5): 1359–1368.
    CrossRefPubMed
  9. Cristofanilli M, Pierga JY, Reuben J, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Crit Rev Oncol Hematol. 2019; 134: 39–45.
    CrossRefPubMed
  10. Li X, Ye M, Zhang W, et al. Liquid biopsy of circulating tumor DNA and biosensor applications. Biosens Bioelectron. 2019; 126: 596–607.
    CrossRefPubMed
  11. Leon SA, Green A, Yaros MJ, et al. Radioimmunoassay for nanogram quantities of DNA. J Immunol Methods. 1975; 9(2): 157–164.
    CrossRefPubMed
  12. Gedvilaitė V, Schveigert D, Cicėnas S. Cell-free DNA in non-small cell lung cancer. Acta Med Litu. 2017; 24(2): 138–144.
    CrossRefPubMed
  13. Esposito A, Criscitiello C, Trapani D, et al. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. Curr Oncol Rep. 2017; 19(1): 1.
    CrossRefPubMed
  14. Lui YYN, Chik KW, Chiu RWK, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem. 2002; 48(3): 421–427.
    PubMed
  15. Zheng YWL, Chan KC, Sun H, et al. Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model. Clin Chem. 2012; 58(3): 549–558.
    CrossRefPubMed
  16. Herbreteau G, Vallée A, Knol AC, et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018; 9(38): 25265–25276.
    CrossRefPubMed
  17. Underhill HR, Kitzman JO, Hellwig S, et al. Fragment Length of Circulating Tumor DNA. PLoS Genet. 2016; 12(7): e1006162.
    CrossRefPubMed
  18. Li Li, Zhang J, Jiang X, et al. Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res. 2018; 8(10): 1947–1956.
    PubMed
  19. Mouliere F, Robert B, Arnau Peyrotte E, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 2011; 6(9): e23418.
    CrossRefPubMed
  20. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001; 61(4): 1659–1665.
    PubMed
  21. Lapin M, Oltedal S, Tjensvoll K, et al. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med. 2018; 16(1): 300.
    CrossRefPubMed
  22. Rack B, Schindlbeck C, Jückstock J, et al. SUCCESS Study Group. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014; 106(5).
    CrossRefPubMed
  23. Gray ES, Rizos H, Reid AL, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015; 6(39): 42008–42018.
    CrossRefPubMed
  24. Cavallone L, Aldamry M, Lafleur J, et al. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR. Cancer Epidemiol Biomarkers Prev. 2019; 28(5): 909–916.
    CrossRefPubMed
  25. Elshimali YI, Khaddour H, Sarkissyan M, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013; 14(9): 18925–18958.
    CrossRefPubMed
  26. Kirsch C, Weickmann S, Schmidt B, et al. An improved method for the isolation of free-circulating plasma DNA and cell-free DNA from other body fluids. Ann N Y Acad Sci. 2008; 1137: 135–139.
    CrossRefPubMed
  27. Oellerich M, Schütz E, Beck J, et al. Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci. 2017; 54(3): 205–218.
    CrossRefPubMed
  28. Freidin MB, Freydina DV, Leung M, et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem. 2015; 61(10): 1299–1304.
    CrossRefPubMed
  29. Dawson SJ, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13): 1199–1209.
    CrossRefPubMed
  30. Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018; 16(1): 166.
    CrossRefPubMed
  31. Fleischhacker M, Schmidt B, Weickmann S, et al. Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta. 2011; 412(23-24): 2085–2088.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl